How often Subbu Nambi’s price targets were reached, how fast, and what the stocks did after each call: a 7‑year backtest of 310 ratings, compared with the average Wall Street analyst.
Subbu Nambi of Guggenheim ranks #44 of the 1,000 analysts Exent scores, with a 5.0★ rating and a focus on healthcare. Over a 7‑year lookback, 56.6% of Subbu’s price targets were reached, 4.2 points above the 52.4% average across all analysts.
| Metric | Subbu Nambi | All analysts |
|---|---|---|
| Price‑target hit rate | 56.6% | 52.4% |
| Median days to hit target | 59 days | 91 days |
| Calls up after 12 months | 61.7% | 64.0% |
| Median 12‑month return of calls | +7.2% | +13.4% |
| Hit rate, last 2 years | 55.9% | — |
| Average worst drop after a call | −23.2% | — |
| Ratings in the sample | 310 | — |
| Stocks covered | 28 | — |
| Time to reach the target | Subbu Nambi |
|---|---|
| Under 30 days | 31.5% |
| 30–90 days | 23.3% |
| 90–180 days | 27.4% |
| Over 180 days | 17.8% |
Share of the targets that were reached, by how long they took. Targets are usually set for 12 months.
| Stock | Ratings in the sample |
|---|---|
| GH | 35 |
| GRAL | 27 |
| ILMN | 27 |
| BRKR | 26 |
| VCYT | 25 |
| TEM | 24 |
| TWST | 21 |
| WGS | 18 |
In the past year Subbu’s ratings were 93% Buy, 7% Hold and 0% Sell.
| Date | Stock | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 20, 2026 | FRNM | Initiated Coverage: Buy | Buy | $21.00 |
| Aug 11, 2026 | NTRA | Reiterated: Buy | Buy | $360.00 |
| Aug 6, 2026 | CYRX | Reiterated: Buy | Buy | $16.00 |
| Aug 5, 2026 | GRAL | Reiterated: Buy | Buy | $75.00 |
| Aug 4, 2026 | BRKR | Reiterated: Buy | Buy | $70.00 |
| Aug 4, 2026 | WAT | Reiterated: Buy | Buy | $440.00 |
| Aug 3, 2026 | TEM | Reiterated: Buy | Buy | $65.00 |
| Jul 31, 2026 | VCYT | Reiterated: Buy | Buy | $65.00 |
| Jul 31, 2026 | GH | Reiterated: Buy | Buy | $190.00 |
| Jul 30, 2026 | ILMN | Reiterated: Buy | Buy | $226.00 |
| Jul 30, 2026 | NEOG | Reiterated: Buy | Buy | $12.00 |
| Jul 29, 2026 | ADPT | Reiterated: Buy | Buy | $25.00 |
Live ratings from Subbu Nambi and the other top‑ranked analysts, and the stocks where they agree, are in Exent Stocks Radar.
Exent replays every rating with a price target over a 7‑year lookback: was the target reached, how long it took, and what the stock returned 1, 3, 6 and 12 months after the call. The star rating and rank combine success rate, average return and the number of ratings, so a few lucky calls do not make a top analyst. Statistics as of Jun 24, 2026; ranking updated Oct 15, 2026. How accurate are analyst price targets overall?
Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.
By Exent’s scoring Subbu Nambi ranks #44 of 1,000 with a 5.0★ rating. 56.6% of price targets were reached over a 7-year lookback (all analysts: 52.4%), and 61.7% of calls were up 12 months later. Past accuracy does not guarantee future accuracy.
Subbu Nambi’s success rate is 78.2% by the ranking source and 56.6% by Exent’s price-target hit-rate backtest, with a median of 59 days to reach a target.
Subbu Nambi (Guggenheim) covers 28 stocks, mostly in healthcare. The most frequently rated are GH, GRAL, ILMN, BRKR, VCYT.
Exent tracks 4,000+ analysts, keeps only the elite few with proven records, and surfaces the Gems where they agree.
Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.